<DOC>
	<DOC>NCT01674985</DOC>
	<brief_summary>The purpose of this study is to investigate whether infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC) combining decitabine and cytarabine chemotherapy can improve outcomes in myelodysplastic syndromes (MDS) patients.</brief_summary>
	<brief_title>Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>patients 10 to 90 years old with primary or treatmentrelated MDS or chronic myelomonocytic leukemia; International Prognostic Scoring System(IPSS) intermediate1,intermediate2,or high risk; bone marrow blasts &gt; 11% or &lt;= 10% and poor cytogenetics; lack of an HLAidentical donor; Eastern Cooperative Oncology Group (ECOG) performance status 02; adequate cardiac and hepatorenal functions. have an HLAidentical donor</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Decitabine</keyword>
	<keyword>microtransplantation</keyword>
	<keyword>myelodysplastic syndromes</keyword>
	<keyword>chemotherapy</keyword>
</DOC>